Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Phase 1 Completed
85 enrolled
ALPHA
Phase 1 Completed
50 enrolled
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693.
Phase 1 Completed
35 enrolled
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Phase 1 Completed
26 enrolled
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Phase 1 Completed
20 enrolled
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
Phase 1 Completed
12 enrolled
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase 1 Completed
23 enrolled
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Phase 1 Completed
3 enrolled
ATECRAB
Phase 1 Completed
3 enrolled
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
3 enrolled
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Phase 1 Completed
32 enrolled
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Phase 1 Completed
25 enrolled 31 charts
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
Phase 1 Completed
14 enrolled
A Study of LY3039478 in Participants With Advanced Cancer
Phase 1 Completed
247 enrolled 53 charts
A Study of LP-118 in Patients With Advanced Tumors
Phase 1 Completed
68 enrolled
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
Phase 1 Completed
7 enrolled
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Phase 1 Completed
69 enrolled
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Phase 1 Completed
114 enrolled
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
Phase 1 Completed
3 enrolled 8 charts
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
Phase 1 Completed
104 enrolled
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Phase 1 Completed
14 enrolled
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Phase 1 Completed
43 enrolled
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1 Completed
35 enrolled
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Phase 1 Completed
66 enrolled
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 1 Completed
50 enrolled
MK-1454-001
Phase 1 Completed
156 enrolled 20 charts
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Phase 1 Completed
17 enrolled
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
Phase 1 Completed
29 enrolled 11 charts
ASP8374 + Cemiplimab in Recurrent Glioma
Phase 1 Completed
14 enrolled
ELM-1
Phase 1 Completed
200 enrolled
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Phase 1 Completed
18 enrolled
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Phase 1 Completed
28 enrolled
CAMPOLINA
Phase 1 Completed
35 enrolled
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Phase 1 Completed
23 enrolled
MK-1026-002
Phase 1 Completed
7 enrolled
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
Phase 1 Completed
13 enrolled
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Phase 1 Completed
26 enrolled
Vaccine Responsiveness After CAR-T Cell Therapy
Phase 1 Completed
49 enrolled
ARC-12
Phase 1 Completed
94 enrolled
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Phase 1 Completed
18 enrolled
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Phase 1 Completed
13 enrolled
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Phase 1 Completed
26 enrolled
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase 1 Completed
50 enrolled
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Phase 1 Completed
85 enrolled
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Phase 1 Completed
45 enrolled
Haplo Peripheral Blood Sct In GVHD Prevention
Phase 1 Completed
25 enrolled
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Phase 1 Completed
55 enrolled